Dataset opportunity
13Therapeutics — 医疗影像数据集机会
13Therapeutics 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
67.8
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
收购
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球诊断人工智能市场在 2025 年的估值为 20 亿美元，预计到 2033 年将达到 97 亿美元，复合年增长率为 21.7%。
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-08-03
New blood marker could help track MS progression and monitor treatment response
news-medical.net ↗ - 📰press2026-08-03
KKR to take Integer private for $5.7B
medtechdive.com ↗ - 📰press2026-08-03
Netzhautchip PRIMA startet in 30 europäischen Ländern
devicemed.de ↗ - 📰press2026-08-03
Beyond the Status Report: Using LLMs to Reveal the True State of SaMD Development
medtechintelligence.com ↗ - 📰press2026-08-03
Webcast tonight: Autism & mental health comorbidities
medicalrepublic.com.au ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 📣Press / announcement
获得超过 1000 万美元的 NIH 同行评审研究资助
source ↗
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — 许可权待明确 · 个人身份信息/受监管
Buyer persona
医疗人工智能与诊断影像公司
13Therapeutics 持有一个医疗影像数据集，其中包含临床前和体外图像，并附有相关的医疗记录和监管证据。这些数据结构化，可直接用于训练和验证诊断人工智能算法，其核心价值源于独家授权自俄勒冈健康与科学大学 (OHSU) 的研究。
该数据服务于快速扩张的全球诊断人工智能市场，该市场在 2025 年的估值为 20 亿美元，预计到 2033 年将达到 97 亿美元，复合年增长率为 21.7%。[5] 尽管存在非标准化格式或提取团队带宽有限等访问复杂性，但该数据集的稀有性和独特的研究来源使其成为旨在竞争这一高增长领域的 AI 开发者的宝贵资产。⚠ 尽职调查（有价值的数据，可协商的访问权限）：数据源自独家授权自俄勒冈健康与科学大学 (OHSU) 的研究；临床前和体外数据可能存储在非标准化的实验室格式中；小型研究团队在数据提取方面可能带宽有限 · 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 13Therapeutics 持有专有且研究级的数据集，该数据集已通过超过 1000 万美元的联邦 SBIR 赠款和内部临床前测试得到验证。这一独特的生物反应数据集合非常适合寻求训练和验证新型算法的诊断人工智能公司。在全球诊断人工智能市场预计到 2033 年将达到97 亿美元的背景下，该数据集为开发下一代医疗影像解决方案提供了难得的竞争优势。
See dimension details ↓- Dataset Specificity90
主导的“医疗记录”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
由于全球诊断人工智能市场的快速扩张（复合年增长率为 21.7%），买家需求异常高，因为公司竞相开发更优越的诊断工具。[5]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 个命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License70
所有权=已拥有，许可=权利不明确
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 个数据需求信号（1 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高，5 个近期外部信号 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ 良好目标 — 这是一家小型、临床前阶段的药物开发公司，其核心业务是创建肽疗法，使其研究产生的专有数据成为一项休眠副产品，非常适合。问题：该公司非常小，仅列出 4 名员工，这可能会影响其数据运营的规模。公开信息，如访谈和专利申请，似乎可追溯到 2013 年左右，这引发了对当前水平的疑问。
- Deep Qualification80
⚠ 需要审查 — 目标是一家药物开发公司，持有临床前数据作为其研发的副产品；数据不是其核心产品，其权利可能受到 OHSU 的独家许可限制。[许可受限]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
这些证据证实了专有生物反应数据的存在，包括来自临床前动物模型的医疗影像，这对于 AI 开发人员训练关于新型生物效应的模型来说是高度需求的。
Industrial data
该公司的专利肽组合表明拥有底层研究数据，可能包括跟踪特定细胞内信号通路的实验的时间序列数据，这对于药物发现人工智能中的预测建模非常有价值。
Regulatory records
获得超过 1000 万美元的多个 SBIR 赠款证明了生成大量结构化研究数据的历史，这些数据已成功通过严格的联邦审查，这是需要可靠、文档齐全的数据集的买家的一项关键质量信号。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
13Therapeutics Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in diagnostics market was valued at USD 2.0 billion in 2025 and is projected to reach USD 9.7 billion by 2033, at a CAGR of 21.7% (source: Grand View Research). [5]. Investment score 67.8/100 (confidence 0.49). Recommended action: Acquire.
From the marketplace
Explore live data opportunities
Althensensors — 工业传感器数据集机会
View opportunity →机动性Jachttrans — 机动性遥测数据集机会
View opportunity →工业Eco Stor — 维护日志数据集机会
View opportunity →